BioNTech SE Sponsored ADR $BNTX Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. increased its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 79.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 760,675 shares of the company's stock after acquiring an additional 337,412 shares during the period. Assenagon Asset Management S.A. owned 0.30% of BioNTech worth $74,774,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in BNTX. Integrated Wealth Concepts LLC acquired a new position in BioNTech during the second quarter valued at approximately $39,000. Farther Finance Advisors LLC raised its position in shares of BioNTech by 31.5% in the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company's stock valued at $48,000 after purchasing an additional 118 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of BioNTech by 1,012.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company's stock worth $53,000 after buying an additional 506 shares during the last quarter. Rockefeller Capital Management L.P. lifted its stake in shares of BioNTech by 328.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company's stock worth $177,000 after buying an additional 1,423 shares during the last quarter. Finally, Quintet Private Bank Europe S.A. lifted its stake in shares of BioNTech by 232.8% in the third quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company's stock worth $188,000 after buying an additional 1,341 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

Insider Buying and Selling at BioNTech

In related news, CEO Ugur Sahin sold 36,209 shares of BioNTech stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $95.37, for a total value of $3,453,252.33. Following the completion of the transaction, the chief executive officer directly owned 36,209 shares of the company's stock, valued at $3,453,252.33. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 807,209 shares of company stock valued at $79,246,837 in the last three months. Company insiders own 19.20% of the company's stock.

BioNTech Trading Down 2.8%

Shares of BNTX stock opened at $87.71 on Friday. The company has a market capitalization of $22.18 billion, a P/E ratio of -11.20 and a beta of 1.25. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $98.98 and a 200 day moving average price of $95.27.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same period in the previous year, the business posted ($1.60) EPS. The business's quarterly revenue was down 59.5% on a year-over-year basis. Research analysts forecast that BioNTech SE Sponsored ADR will post -6.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on BNTX. Argus assumed coverage on BioNTech in a research note on Thursday, October 8th. They issued a "hold" rating on the stock. Morgan Stanley decreased their target price on BioNTech from $115.00 to $114.00 and set an "overweight" rating for the company in a research note on Wednesday, October 7th. Wall Street Zen lowered BioNTech from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioNTech in a report on Friday, October 2nd. Finally, Berenberg Bank set a $140.00 price target on BioNTech in a research report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $125.44.

BioNTech Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.